Rockville, Md.
BioReliance opened a new $24 million, $58,000-sf facility in late September 2000 to provide large-scale, viral gene therapy and drug manufacturing services to biotechnology and pharmaceutical companies. The company will provide bulk manufacturing of the human smallpox vaccine for OraVax, a Cambridge, Mass., biopharmaceutical firm that was recently awarded a $343 million contract for the vaccine by the U.S. Centers for Disease Control.
